| RB1 loss induces quiescent state through downregulation of RAS signaling in mammary epithelial cells. | RB1 loss induces quiescent state through downregulation of RAS signaling in mammary epithelial cells.
Gong L, Voon DC, Nakayama J, Takahashi C, Kohno S., Free PMC Article | 06/3/2024 |
| CD74-ROS1 L2026M mutant enhances autophagy through the MEK/ERK pathway to promote invasion, metastasis and crizotinib resistance in non-small cell lung cancer cells. | CD74-ROS1 L2026M mutant enhances autophagy through the MEK/ERK pathway to promote invasion, metastasis and crizotinib resistance in non-small cell lung cancer cells.
Xu X, Li Y, Xu R, Meng Y, Li Z, Zuo D, Wu Y. | 03/15/2024 |
| Inflammatory Myofibroblastic Tumor With ROS1 Gene Fusions in Children and Young Adolescents. | Inflammatory Myofibroblastic Tumor With ROS1 Gene Fusions in Children and Young Adolescents.
Schoot RA, Orbach D, Minard Colin V, Alaggio R, Di Carlo D, Corradini N, Mercolini F, Milano GM, van Noesel MM, Rome A, Dall'Igna P, Pajtler K, Sparber-Sauer M, Ferrari A, Casanova M. | 11/1/2023 |
| Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors. | Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors.
Iyer SR, Nusser K, Jones K, Shinde P, Keddy C, Beach CZ, Aguero E, Force J, Shinde U, Davare MA., Free PMC Article | 10/30/2023 |
| Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients. | Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients.
Glaser M, Rasokat A, Prang D, Nogova L, Wömpner C, Schmitz J, Bitter E, Terjung I, Eisert A, Fischer R, John F, von Levetzow C, Michels S, Riedel R, Ruge L, Scharpenseel H, Siebolts U, Merkelbach-Bruse S, Buettner R, Brägelmann J, Wolf J, Scheffler M. | 09/20/2023 |
| Therapeutical Options in ROS1-Rearranged Advanced Non Small Cell Lung Cancer. | Therapeutical Options in ROS1-Rearranged Advanced Non Small Cell Lung Cancer.
Stanzione B, Del Conte A, Bertoli E, De Carlo E, Revelant A, Spina M, Bearz A., Free PMC Article | 08/19/2023 |
| "Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer". | "Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer".
Dyrbekk APH, Warsame AA, Suhrke P, Ludahl MO, Moe JO, Eide IJZ, Lund-Iversen M, Brustugun OT., Free PMC Article | 06/2/2023 |
| ROS1 as a possible prognostic biomarker of cervical adenocarcinoma: An exploratory analysis with next-generation sequencing. | ROS1 as a possible prognostic biomarker of cervical adenocarcinoma: An exploratory analysis with next-generation sequencing.
Machida H, Matsuo K, Tanaka M, Kitatani K, Takase A, Yokoyama K, Kajiwara H, Yasaka M, Ikeda M, Yoshida H, Hirasawa T, Mikami M. | 03/29/2023 |
| SNP rs9387478 at ROS1-DCBLD1 Locus is Significantly Associated with Lung Cancer Risk and Poor Survival in Indian Population. | SNP rs9387478 at ROS1-DCBLD1 Locus is Significantly Associated with Lung Cancer Risk and Poor Survival in Indian Population.
Chongtham J, Pandey N, Sharma LK, Mohan A, Srivastava T., Free PMC Article | 11/5/2022 |
| ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer. | ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer.
Akhoundova D, Hussung S, Sivakumar S, Töpfer A, Rechsteiner M, Kahraman A, Arnold F, Angst F, Britschgi C, Zoche M, Moch H, Weber A, Sokol E, Fritsch RM., Free PMC Article | 10/29/2022 |
| FISH patterns of ROS1, MET, and ALK with a correlation of ALK immunohistochemistry in lung cancer: a case for introducing ALK immunohistochemistry 'Equivocal' interpretation category in the Ventana anti-ALK (D5F3) CDx assay - A tertiary cancer center experience. | FISH patterns of ROS1, MET, and ALK with a correlation of ALK immunohistochemistry in lung cancer: a case for introducing ALK immunohistochemistry 'Equivocal' interpretation category in the Ventana anti-ALK (D5F3) CDx assay - A tertiary cancer center experience.
Singh A, Kumar R, Shetty O, Desai S, Rane S. | 06/18/2022 |
| ROS1 altered breast cancers - a distinctive molecular subtype of PR- metastatic breast cancers: Expanding the scope of targeted therapeutics. | ROS1 altered breast cancers - a distinctive molecular subtype of PR- metastatic breast cancers: Expanding the scope of targeted therapeutics.
Krishnamurthy K, Deb A, Alghamdi S, Schwartz M, Cusnir M, Sriganeshan V, Poppiti R. | 06/11/2022 |
| Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing' strategy in advanced NSCLC in Spain. | Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing' strategy in advanced NSCLC in Spain.
Rojo F, Conde E, Torres H, Cabezón-Gutiérrez L, Bautista D, Ramos I, Carcedo D, Arrabal N, García JF, Galán R, Nadal E., Free PMC Article | 03/26/2022 |
| Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer. | Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.
Lin JJ, Choudhury NJ, Yoda S, Zhu VW, Johnson TW, Sakhtemani R, Dagogo-Jack I, Digumarthy SR, Lee C, Do A, Peterson J, Prutisto-Chang K, Malik W, Hubbeling HG, Langenbucher A, Schoenfeld AJ, Falcon CJ, Temel JS, Sequist LV, Yeap BY, Lennerz JK, Shaw AT, Lawrence MS, Ou SI, Hata AN, Drilon A, Gainor JF., Free PMC Article | 03/19/2022 |
| Uterine inflammatory myofibroblastic tumor: First report of a ROS1 fusion. | Uterine inflammatory myofibroblastic tumor: First report of a ROS1 fusion.
Bennett JA, Wang P, Wanjari P, Diaz L, Oliva E. | 03/19/2022 |
| Clinical characteristics of non-small cell lung cancer patients with EGFR mutations and ALK&ROS1 fusions. | Clinical characteristics of non-small cell lung cancer patients with EGFR mutations and ALK&ROS1 fusions.
Liu Q, Huang Q, Yu Z, Wu H., Free PMC Article | 03/12/2022 |
| GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. | GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types.
Sievers P, Stichel D, Sill M, Schrimpf D, Sturm D, Selt F, Ecker J, Kazdal D, Miele E, Kranendonk MEG, Tops BBJ, Kohlhof-Meinecke P, Beschorner R, Kramm CM, Hasselblatt M, Reifenberger G, Capper D, Wesseling P, Stenzinger A, Milde T, Korshunov A, Witt O, Pfister SM, Wick W, von Deimling A, Jones DTW, Sahm F., Free PMC Article | 02/26/2022 |
| Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement. | Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement.
Krawczyk P, Grenda A, Terlecka P, Błach J, Wojas-Krawczyk K, Kucharczyk T, Chmielewska I, Kieszko R, Jarosz B, Gil M, Reszka K, Milanowski J., Free PMC Article | 01/22/2022 |
| Validation of ROS1 by immunohistochemistry against fluorescent in situ hybridisation on cytology and small biopsy samples in a large teaching hospital. | Validation of ROS1 by immunohistochemistry against fluorescent in situ hybridisation on cytology and small biopsy samples in a large teaching hospital.
Narine N, Wallace A, Dore J, O'Leary-Jackson S, Al Najjar H, Bailey S, Khan K, Teng B, Qasim M, Shelton D, Holbrook M, Abbasi S, Carter M, Irion L, Al-Habba S, Lindsay C, Blackhall F, Rana D. | 01/22/2022 |
| Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations. | Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations.
Guaitoli G, Bertolini F, Bettelli S, Manfredini S, Maur M, Trudu L, Aramini B, Masciale V, Grisendi G, Dominici M, Barbieri F., Free PMC Article | 01/8/2022 |
| Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma. | Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma.
Ekin Z, Nart D, Savaş P, Veral A., Free PMC Article | 12/4/2021 |
| EGFR mutations and ROS1 and ALK rearrangements in a large series of non-small cell lung cancer in South India. | EGFR mutations and ROS1 and ALK rearrangements in a large series of non-small cell lung cancer in South India.
Tarigopula A, Ramasubban G, Chandrashekar V, Govindasami P, Chandran C., Free PMC Article | 12/4/2021 |
| Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing. | Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing.
Cui M, Han Y, Li P, Zhang J, Ou Q, Tong X, Zhao R, Dong N, Wu X, Li W, Jiang G., Free PMC Article | 11/13/2021 |
| Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer-A Cost-Efficient Strategy in a Public Healthcare System. | Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer-A Cost-Efficient Strategy in a Public Healthcare System.
Makarem M, Ezeife DA, Smith AC, Li JJN, Law JH, Tsao MS, Leighl NB., Free PMC Article | 10/30/2021 |
| Clinical, morphologic, and genomic findings in ROS1 fusion Spitz neoplasms. | Clinical, morphologic, and genomic findings in ROS1 fusion Spitz neoplasms.
Gerami P, Kim D, Compres EV, Zhang B, Khan AU, Sunshine JC, Quan VL, Busam K., Free PMC Article | 10/23/2021 |